MYGN

Myriad Genetics' stock has experienced notable events in the past six months. As of May 8, 2026, the stock was trading at $4.29, with a 52-week range of $3.75 to $8.59, decreasing by 30.2% since the beginning of 2026. In May 2026, the company reported its first-quarter 2026 financial results, which included a GAAP net loss of $34.1 million and an adjusted loss per share of $0.09, missing analyst expectations and leading to a stock sell-off. Despite the miss, management reaffirmed its full-year 2026 revenue guidance of $860-$880 million. The company also announced FDA approval in April 2026 for its MyChoice CDx test for prostate cancer patients in Japan. In March 2026, Myriad Genetics received FDA approval for the MyChoice CDx test as a companion diagnostic for Zejula for ovarian cancer patients and commercially launched Precise MRD with select community oncologists. In November 2025, the company reported its third-quarter 2025 financial results, with revenue of $205.7 million, a 4% decrease year-over-year, but flat when excluding certain headwinds, while hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively.